North America was the largest contributor to the active pharmaceutical ingredients market in 2020. This is mainly attributed to the growing incidence of chronic diseases, the increased government focus on generic drugs, the growing demand for biologics and specialty drugs and technological advancements in API manufacturing processes. , In the region.
The International Agency for Research on Cancer (IARC) reports that 10 million cancer deaths and 19.3 million new cancer cases were recorded in 2020. According to the IARC, 1 in 5 people in the world develop cancer in during his life. In addition, the World Health Organization (WHO) estimates that around 17.9 million human lives were lost due to cardiovascular disease (CVD) in 2019. Further, the WHO states that more than 3 million people die each year from chronic obstructive pulmonary disease (COPD), accounting for more than 6% of deaths worldwide.
The growing incidence of these chronic diseases is expected to propel the active pharmaceutical ingredients market at a CAGR of 6.9% during the forecast period (2021-2030). Additionally, P&S Intelligence states that the growing geriatric population will help grow market revenues from $ 184,311.2 million in 2020 to $ 357,005.7 million by 2030. According to the Department of Business Economic and Social Affairs (UNDESA), the number of people aged 65 and above will rise from 727 million in 2020 to around 1.5 billion by 2050.
Get sample pages in this report at: https://www.psmarketresearch.com/market-analysis/active-pharmaceutical-ingredient-api-market/report-sample
Nowadays, captive manufacturers and merchants produce generic and innovative APIs, available through online and offline channels. In contemporary times, innovative APIs are used in greater quantities due to the growing interest of pharmaceutical companies in the development of new and more effective drugs. In the years to come, captive manufacturers will become the largest producer of APIs due to the strict quality control and drug safety guidelines the pharmaceutical industry faces and the higher budgets captive companies have for the production. research and development (R&D).
The therapeutic applications segment of the active pharmaceutical ingredients market is categorized into cardiovascular disease, communicable disease, diabetes, oncology, pain management, respiratory disease, and others. Of these, the oncology category held the largest market share in 2020, mainly due to the high burden of cancer and the high demand for highly potent APIs (HPAPIs) for the treatment of cancer. WHO estimates that cancer caused about 10 million deaths worldwide in 2020. It also reports that 1.93 million, 2.21 million and 2.26 million people have been diagnosed with colon and cancer. rectum, lung and breast, respectively, in 2020.
In recent years, pharmaceutical companies, such as Eli Lilly and Company, Mallinckrodt plc, Merck & Co. Inc., Lupine Limited, Johnson & Johnson, STADA Arzneimittel AG, AbbVie Inc., MSN Laboratories Pvt. Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca plc and Sanofi, have introduced new products, entered into collaborations and partnerships and expanded their production capacities, to offer APIs to more clients. For example, in July 2021, Pfizer Inc. collaborated with Arvinas Inc. to develop and sell the estrogen receptor protein degradator PROTAC ARV-471.
Browse detailed report on Global Active Pharmaceutical Ingredients Market Size and Growth Forecast till 2030
Globally, the North American active pharmaceutical ingredients market is expected to generate the highest revenue during the forecast period, owing to the increasing burden of chronic diseases, increasing demand for specialty drugs and products. biologics, the government’s growing focus on generic drugs, increasing technological advancements and increasing number of R&D initiatives in the pharmaceutical industry. In addition, the growing public awareness of many lifestyle-related diseases, such as diabetes, is expected to drive demand for APIs in the region.
Therefore, the surge in chronic disease cases and the growing aging of the population will fuel the use of APIs globally.
Breakdown of market size by segment
By type of manufacturer
- Generic APIs
- Innovative APIs
By type of synthesis
By type of drug
- Prescription drugs
- Over-the-counter (OTC) drugs
By therapeutic application
- Communicable diseases
- Cardiovascular disease (CVD)
- Pain management
- Respiratory diseases
By distribution channel
- North America
- Asia Pacific
- South Korea
- Latin America
- Middle East and Africa
- Saudi Arabia
- South Africa
Browse other related reports
Generic drugs market – Globally, Asia-Pacific generated the highest generic drug market revenue in 2019, and this trend is expected to continue in the years to come.
Psoriasis Drugs Market – Geographically, North America accounted for the largest share of the psoriasis drug market during the historical period. This may be due to the growing awareness of newly developed drugs and the increase in per capita income in the region.
Company Name: P&S Intelligence
E-mail: Send an email
Address:Noida Sector 2
State: AT THE TOP